$AARD News

Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ...

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

HC Wainwright & Co. Reiterates Neutral on Aardvark Therapeutics, Announces $6 Price Target

Several Insiders Invested In Aardvark Therapeutics Flagging Positive News

Aardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path Forward

B. Riley Securities Maintains Buy on Aardvark Therapeutics, Lowers Price Target to $7

FDA hold puts Aardvark Prader-Willi drug in limbo

BTIG Downgrades Aardvark Therapeutics to Neutral

FDA Halts Aardvark Therapeutics Rare Disease Study

Morgan Stanley Downgrades Aardvark Therapeutics to Underweight, Lowers Price Target to $3

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

Aardvark Therapeutics Says FDA Places Full Clinical Hold On Its Investigational New Drug Application For ARD-101 Related To Prior Announced Voluntary Pause

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Why Aardvark Therapeutics (AARD) Paused Late-Stage ARD-101 Trials After Cardiac Findings

BTIG Reiterates Buy on Aardvark Therapeutics, Maintains $9 Price Target

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Aardvark Therapeutics Files Prospectus To Offer Up To $400M In Securities

Aardvark Therapeutics Announces Voluntary Pause Of The Phase 3 HERO And OLE Trials Evaluating ARD-101 For The Treatment Of Hyperphagia In Individuals With Prader-Willi Syndrome, Further Guidance On The Program Expected In Q2 2026